| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Ordinary Shares | Award | $0 | +19.3K | +12.87% | $0.00 | 169K | 26 Mar 2025 | See footnote | F1, F2 |
| transaction | NAMS | Ordinary Shares | Options Exercise | $0 | +45.5K | +133.77% | $0.00 | 79.5K | 26 Mar 2025 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Restricted Stock Unit | Award | +45.5K | 45.5K | 26 Mar 2025 | Ordinary Shares | 45.5K | Direct | F3, F4, F5 | ||||
| transaction | NAMS | Restricted Stock Unit | Options Exercise | -45.5K | -100% | 0 | 26 Mar 2025 | Ordinary Shares | 45.5K | Direct | F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | Reflects ordinary shares issued to Futurum B.V. ("Futurum") for the benefit of the Reporting Person on March 26, 2025 as earnout shares pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain shareholders would receive additional ordinary shares of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of November 22, 2022, the date of closing under the BCA (the "Closing Date"). Futurum's right to receive the earnout shares became fixed and irrevocable on the Closing Date. |
| F2 | The ordinary shares are held by Futurum for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum. |
| F3 | Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share. |
| F4 | Upon grant, all of the RSUs were fully-vested. |
| F5 | The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. |